Backgrounds and objectives Clopidogrel, an inhibitor of platelet ADP P2Y12 receptors,
plays an important role in the prevention of stent thrombosis. However, some patients do not …

The antiplatelet drug clopidogrel is a commonly prescribed therapy in patients with acute
coronary syndrome. However, its clinical efficacy is hampered by a wide inter-patient …

We evaluated the effect of the CYP2C19 genotype on the pharmacokinetics and
pharmacodynamcis of clopidogrel. Twenty‐four subjects were divided into three groups on …

Antiplatelet agents are the mainstay treatment in the prevention and management of
atherothrombotic complications. However, a substantial interpatient variability in response to …

Objectives: This study assessed the effect of pharmacogenetics on the antiplatelet effect of
clopidogrel. Background: Variability in clopidogrel response might be influenced by …

Whether the current pharmacogenetic knowledge of clopidogrel could be translated into
Chinese clinical practice is yet to be defined. To address this issue, we assessed the relation …

Clopidogrel inhibits platelet activation and aggregation by blocking the P2Y12 receptor.
Dual antiplatelet therapy with clopidogrel and aspirin is recommended treatment by current …

What is known and objective The reasons of clopidogrel (CLP) resistance are still unclear.
The response to CLP may be influenced by both genetic and non‐genetic factors. Among …

Abstract Background and Objectives Resistance to the antiplatelet treatment with clopidogrel
has both genetic and non-genetic causes. Polymorphic variants of cytochrome P450 3A4 …

An extensive investigation on pharmacokinetics of clopidogrel and its metabolites as well as
pharmacodynamics of the drug was performed in patients with cardiovascular disease …